Does This Pharma Company's Lead Asset Make it a Buy Today? [The Motley Fool]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: The Motley Fool
Bipolar disorder is relatively common, with .8% of adults, or 6 million Americans, reporting symptoms over a -month period. But the market is underserved; in particular, only a limited number of pharmaceutical companies have succeeded in launching treatments for bipolar-related depression. Hence, therecent clinical successIntra-Cellular Therapies(NASDAQ:ITCIBut does this clinical success make Intra-Cellular Therapies a Buy? Let's find out.Image source: Getty Images.The portfolio targets multiple neuropsychiatric and neurological disordersIntra-Cellular Therapies secured its first-ever U.S. Food and Drug Administration (FDA) approval for Caplyta (lumateperone capsules) to treat schizophrenia in December 09. Launched in late March, Caplyta earned $.9 million in sales in the second quarter of fiscal 00. More than 9% of people covered by Medicare Part D and Medicaid programs now have access to this schizophrenia drug.Intra-Cellular Therapies has big label expansion plans for lumateperone.
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $100.00 to $107.00. They now have a "buy" rating on the stock.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $82.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $82.00 to $96.00. They now have a "buy" rating on the stock.MarketBeat
- Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success [Yahoo! Finance]Yahoo! Finance
ITCI
Earnings
- 2/22/24 - Beat
ITCI
Sec Filings
- 4/18/24 - Form 8-K
- 4/18/24 - Form 424B5
- 4/16/24 - Form 8-K
- ITCI's page on the SEC website